Logotype for Helen of Troy Limited

Helen of Troy (HELE) Q4 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Helen of Troy Limited

Q4 2026 earnings summary

23 Apr, 2026

Executive summary

  • Net sales for FY26 were $1.786 billion, down from $1.908 billion in FY25, with Q4 sales at $470 million, reflecting tariff-related disruptions, softer retail demand, and strategic investments; Olive & June acquisition and pricing actions partially offset declines.

  • Adjusted diluted EPS was $0.83 for Q4 and $3.55 for FY26, both down sharply from the prior year; GAAP results reflect significant non-cash asset impairment charges.

  • Free cash flow for FY26 was $131.9 million, up from $83.1 million in FY25, with $103.1 million generated in Q4; cash flow prioritized for debt reduction.

  • $136 million in debt was paid down during FY26, supported by proceeds from the sale of the Southaven, MS distribution facility and working capital efficiency initiatives.

  • Organizational changes and operational rigor were implemented to address challenges, prioritize brand health, and drive future positioning.

Financial highlights

  • Q4 consolidated sales declined 3.3% year-over-year to $470 million, outperforming outlook due to pricing actions and Olive & June's contribution.

  • FY26 gross profit margin was 45.7% (down 220 bps YoY); Q4 gross margin was 44.6% (down 400 bps), mainly due to higher tariffs, inventory obsolescence, and increased promotional expense.

  • Adjusted operating margin for FY26 was 8.3% (down 490 bps YoY); Q4 was 8.3% (down 710 bps); adjusted EBITDA margin for FY26 was 10.4%.

  • Adjusted diluted EPS for FY26 was $3.55 (vs. $7.17 in FY25); Q4 was $0.83 (vs. $2.33 prior year).

  • Inventory ended at $456 million, flat year-over-year despite $34 million in incremental tariff costs; debt at $781 million, net leverage ratio 3.87x.

Outlook and guidance

  • FY27 net sales expected at $1.751–$1.822 billion; Home and Outdoor $854–$882 million, Beauty and Wellness $897–$940 million.

  • Adjusted EBITDA guidance: $190–$197 million; adjusted EPS: $3.25–$3.75; GAAP diluted EPS: $3.57–$4.18.

  • Free cash flow expected at $85–$100 million; capital expenditures $28–$32 million focused on innovation and supply chain diversification.

  • Net leverage ratio targeted at ~3.2x or lower by year-end; adjusted effective tax rate 25%–27%.

  • Outlook assumes tariffs as of April 2026 remain, no major commodity or supply disruptions, and constant FX rates.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more